Riociquat studied in early PSS w/ mRSS 10–22 and showed a trend to decrease mRSS (p=0.08) & no effect on lungs. But subanalysis of SSc-ILD showed significant improvements in FVC. #EULAR19 OP0183 https://t.co/fP6snUHU1r